PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 8, 2025American Journal of Respiratory and Critical Care Medicine0 citationsOpen Access

Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

View Full Paper
MNMattia NigroSAStefano Aliberti

Key Points

  • Dipeptidyl peptidase-1 inhibitors may influence treatment outcomes in bronchiectasis, as explored in this analysis.
  • The study discusses treatment complexities, emphasizing the interdependence of various drugs in managing bronchiectasis.
  • Observational analysis of treatment impacts suggests that no drug operates in isolation, affecting bronchiectasis outcomes.
  • Understanding the role of dipeptidyl peptidase-1 inhibitors may inform future treatment strategies for bronchiectasis.

Abstract

"Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nigro et al. (2025) studied this question.

synapsesocial.com/papers/68e6679587ecc93a24d1748ahttps://doi.org/10.1164/rccm.202508-2056vp
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2021 · 13,613 citations
  2. 2Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study2024 · 79 citations
  3. 3Bronchiectasis management in adults: state of the art and future directions2024 · 105 citations
  4. 4Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis2020 · 364 citations
  5. 5Adult Patients With Bronchiectasis2016 · 436 citations